Prevalence of COVID-19 Infection in a Cohort of Patients Infected by the HIV and Patients Taking PrEP

Hôpital Européen Marseille600 enrolled

Overview

The purpose of the study is to assess seroprevalence of COVID-19 infection in a cohort of HIV + patients and in a cohort of patients taking PrEP by emtricitabine / tenofovir.

Study Type

OBSERVATIONAL

Enrollment

600

Conditions

Covid19 Virus-HIV

Interventions

Serology test for COVID-19DIAGNOSTIC_TEST

ELISA test

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Aged ≥ 18 years * patients infected by the HIV on treatment * patients taking PreP (Pre-exposure prophylaxis (PrEP)) * Being affiliated with or benefiting from a social security scheme Exclusion Criteria: * Subject to a measure for the protection of justice

Locations (1)

BENNANI

Marseille, France

Outcomes

Primary Outcomes

% of patients with positive serological tests for covid-19

Time frame: 3 months

Secondary Outcomes

Presence and quantification of CD4 / CD8 reactivity to COVID-19 epitopes in patient with positive and negative serological tests for covid-19

% of anti-covid positive cells

Time frame: 3 months

Central Contacts

Myriam BENNANI

CONTACT

0413428351 m.bennani@hopital-europeen.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.